Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Contributed by: Business Wire

Logo

Tags

Research

Infectious Diseases

Biotechnology

Other Health

Health

General Health

Other Science

Science

Oncology

Agendia, Inc.

More Like This

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit

Business Wire associated0

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

(Graphic: Business Wire)

MammaPrint® Reimbursement Indication Extended in Belgium

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024

HER2DX studies presented at ASCO.

ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients